Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Jing HuangBinghe XuYing LiuJunxing HuangPing LuYi BaLin WuYuxian BaiShu ZhangJifeng FengYing ChengJie LiLu WenXianglin YuanChangwu MaChunhong HuQingxia FanXi WangPublished in: Cancer communications (London, England) (2019)
The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. Clinical Trial Registration NCT02319187. Registered on December 9, 2014.